In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given semaglutide alone.U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug Application (IND) for BMF-650, Biomea’s next-generation investigational oral glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), was recently received. Initiation of a Phase I clinical trial in obesity is on ...